JPRN-UMIN000012472招募中2 期
Imatinib discontinuation for Chronic Myelogenou Leukemia-Chronic Phase with 2 years complete molecular remission. - Delightedly Overcome CML Expert Stop TKI Trial (DOMEST Trial)
Epidemiological and Clinical Research Information Network (ECRIN)0 个研究点目标入组 100 人开始时间: 2013年12月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Concurrent malignancy other than CML 2.Women who are pregnant or breastfeeding 3. A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy 4.Subjects with clonal evolution
研究者
相似试验
招募中
2 期
Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.JPRN-UMIN000008999Epidemiological and Clinical Research Information Network(ECRIN)50
已完成
2 期
Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.chronic myeloid leukemiaJPRN-UMIN000005130Epidemiological and Clinical Research Information Network (ECRIN)50
尚未招募
不适用
To stop the use of Imatinib in CML-CP patientsCTRI/2019/07/020407DR BRA IRCH AIIMS
已完成
2 期
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib in Japan adult leukemia study group studyChronic Myeloid Leukemia Chronic phaseJPRN-UMIN000011971Japan Adult Leukemia Study Group62
招募中
不适用
Stop imatinib or dasatinib study in CP-CML patients mainitaining complete molecular response for two yearschronic phase chronic myeloid leukemiaJPRN-UMIN000007944Tokyo Women's Medical University40